Hyloris Pharmaceuticals SA (0AB6.L)

11,70 -1,08 (-8,47%) In data: 05:10PM BST. Mercato aperto.

Hyloris Pharmaceuticals SA

Boulevard Patience et Beaujonc N°3/1
Liège 4000
Belgium
32 4 346 02 07
https://hyloris.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Stijn Van Rompay	Co-Founder, CEO & Director	N/D	N/D	1977
Mr. Thomas Jacobsen	Co-Founder, Chief Business Development Officer & Executive Director	N/D	N/D	1976
Mr. Jean-Luc Vandebroek	Chief Financial Officer	N/D	N/D	1973
Dr. Dietmar Aichhorn Ph.D.	Chief Operating Officer	N/D	N/D	N/D
Mr. Sven Watthy	Investor Relations Manager & Communications manager	N/D	N/D	1991
Mr. Koenraad Van Der Elst	Chief Legal Officer	N/D	N/D	1962

Gli importi risalgono al giorno e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Hyloris Pharmaceuticals SA engages in the develop, manufacture, and deliver pharmaceutical products to address unmet medical needs in cardiovascular health and other major therapeutic areas. It offers cardiovascular products for atrial fibrillation, acute coronary syndrome, advanced heart failure, congestive heart failure, acute coronary syndrome, and coronary heart disease. The company provides Maxigesic IV, a combination of paracetamol and ibuprofen used for post-operative non-opioid pain management; Tranexamic acid RTU, an antifibrinolytic drug for the formation of blood clots; Miconazole/Domiphen Bromide, a topical synergistic combination treatment for Recurrent Vulvovaginal Candidiasis; AlenuraTM, a first-line drug treatment for acute pain in interstitial cystitis/bladder pain syndrome; and Plecoid Agent IV for the treatment of acute myeloid leukemia and small cell lung cancer. It also offers Atomoxetine, an oral liquid for the treatment of patients with attention deficit hyperactivity disorder; HY-029, a liquid formulation of an antiviral drug to treat viral infections; HY-083, a nasal spray for the treatment of idiopathic rhinitis; and HY-088, an oral liquid that treats hypophosphatemia. The company was incorporated in 2012 and is headquartered in Liège, Belgium.

Governance aziendale

L'ISS Governance QualityScore di Hyloris Pharmaceuticals SA al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.